The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies

Inclusion Criteria: * 1\. At the time of initial diagnosis, the age is 18-70 years old, regardless of gender or race * 2\. Morphological analysis showed that the load of lymphoma was ≥ 5% * 3\. Estimated survival time \> 12 weeks * 4\. The main investigator and the attending physician of the patient think that there is no other feasible and effective alternative treatment, such as hematopoietic stem cell transplantation * 5\. Relapsed / refractory B-cell acute lymphocytic leukemia (all): A. objective remission rate (or) of grade 2 or higher bone marrow recurrence B. bone marrow relapse after allogeneic stem cell transplantation (SCT), SCT treatment is more than 6 months and in or state before cart-19 reinfusion C. refractory patients (CR status is not reached after 2 rounds of standard chemotherapy (CR refers to the load of myeloma detected by morphology \< 5%)) D. Philadelphia chromosome positive (Ph +) and tyrosine kinase inhibitor (TKI) treatment failed twice or TKI failed to maintain or E. treatment with allogeneic SCT * 6\. For patients with relapse, CD19 was detected in bone marrow or peripheral blood by flow cytometry within 3 months before admission * 7\. CD19 expression on lymphoma cells: immunohistochemistry \> 15% or flow cytometry \> 30% * 8\. The main organ functions are sound, including: A. renal function: radioisotope glomerular filtration rate \> 60 ml / min / 1.73 m2, or serum creatinine clearance rate in line with relevant age / gender standards B. alanine …